Fig. 2.

SIRT1 does not influence physiological response to short-term PPARα agonist treatment. WT (Sirt1^F/F) and liver-specific Sirt1 mutant (Sirt1^ΔLiv) mice were treated with WY or FF for 5 days. A: liver/body mass ratio, as well as serum triglyceride, cholesterol, and nonesterified fatty acid (NEFA) concentrations, was measured. B: hepatic concentrations of total triglycerides, cholesterol, and NEFA. Significant differences between control and WY or FF treatment are indicated (*P < 0.05). Significant differences between Sirt1^F/F and Sirt1^ΔLiv mice are indicated (†P < 0.05).